US government moves to block Chinese biotechs’ operations
By 
Rebecca Trager2024-03-20T13:53:00
WuXi Apptec and others accused of national security risk, as trade groups back legislation limiting their activities
Pharmaceutical service provider WuXi AppTec, genomics group BGI, and other Chinese biotech companies operating in the US are facing legislative efforts to limit their ability to work with US government agencies or companies that hold (or wish to hold) government contracts.